It has been reported that both NFκB and AP-1 binding sites are present in the promoter region of MMP-1 [48], [49], [50] and enhanced production of MMP-1 is associated with a more aggressive tumor growth, a higher metastatic potential, and poor clinical outcome of malignant tumors [51], [52], [53]. The gene discussed is MMP1; the disease is cancer.